Thank you all!

Thank you all for making possible another successful edition of ALIVE!

We’re delighted to share the resounding success of the ALIVE 2 Congress (Animal Leishmaniosis International Veterinary Event), hosted by the LeishVet group, which took place in the beautiful city of Nice from April 18th to 20th, 2024.

The event’s international scope brought together 239 attendees in person and an additional 212 participants online, representing 32 countries. It was a fantastic opportunity for researchers, practitioners, and dermatologists to gather and exchange knowledge.

Throughout the congress, attendees had the privilege of hearing from esteemed speakers in the field and engaging with a wide range of research presentations, both oral and poster-based.

We extend our heartfelt gratitude to our sponsors and donors – ELANCO, LETI PHARMA, VIRBAC, CEVA, BOEHRINGER INGELHEIM, IDEXX, ECUPHAR, ESCCAP, PETIA, and the Département des Alpes-Maritimes – for their invaluable support. Additionally, we thank the members of the Scientific Committee for their dedication, the Key Note Speakers for their expertise and contribution and all participants for their enthusiasm to make this event a success.

The ALIVE 2 Congress provided an inspiring platform for collaboration and learning, and we’re already looking forward to future opportunities to continue advancing research and clinical management in the field of leishmaniosis.

Gaetano Oliva
President of LeishVet and the Organizing Committee

Honoring Our Sponsors at ALIVE 2, 2024

Honoring Our Sponsors at ALIVE 2, 2024

We're thrilled, once again, to extend our gratitude to the leading companies in the diagnosis, prevention, and treatment of Leishmaniosis for supporting ALIVE 2, 2024

Honoring Our Sponsors at ALIVE 2, 2024

A big thank you to our Corporate Sponsors and Donors, whose generous contributions have enabled the organization of this significant event, taking place in Nice and online from April 18-20, 2024.

Organizing ALIVE 2024 has been a formidable task, but it was made possible through the steadfast support of our sponsors. Their commitment has ensured that we can continue to foster a platform for education, innovation, and dialogue in the fight against Animal Leishmaniosis. We are profoundly thankful for their partnership in making ALIVE 2024 a reality, advancing both the conference’s success and the global health mission.

Our Ruby sponsors are:

Our Sapphire sponsor is:

Our Turquoise sponsors are:

Our Donor are:

The sponsors and donors will be present in the Hotel Radisson Blu and we encourage you to catch up with their latest developments during the Poster and Commercial Exhibition breaks – where the coffee breaks will be served.  Each of them will have their own space where you will be able to find literature and speak with their representatives.

Thank you, sponsors and donors, for your continued support

We look forward to seeing you at ALIVE 2 either Online or in Nice!

Discover Cutting-Edge Insights in Canine Leishmaniosis with Dr. Lluis Ferrer at Leishvet ALIVE 2024

Discover Cutting-Edge Insights in Canine Leishmaniosis with Dr. Lluis Ferrer at LeishVet ALIVE 2 2024

LeishVet ALIVE 2, 2024 is a unique convergence of expertise and innovation, focusing on Leishmaniosis. Among the esteemed speakers is Dr. Lluis Ferrer, whose insights into canine leishmaniosis are eagerly anticipated by veterinary professionals and researchers alike.

Meet Dr. Lluis Ferrer: A Pillar in Veterinary Dermatology

Dr. Ferrer embarked on his distinguished career by obtaining a DVM degree in 1981, followed by a PhD in 1985, both from the University of Zaragoza, Spain. His pursuit of excellence continued as he earned a Master’s degree in Animal Pathology in 1983 from the Veterinary School of Hannover, Germany. In 1994, he reached a significant milestone by becoming a Board-Certified Dermatologist through the European College of Veterinary Dermatology. His tenure as a lecturer at the Cummings School of Veterinary Medicine at Tufts University has been marked by widespread recognition and respect for his academic contributions.

Dr. Ferrer’s tenure at the Universitat Autònoma de Barcelona’s Veterinary School since 1985 has been marked by his impactful contributions in teaching Pathology and Dermatology. His time at this renowned university is not only noted for his educational role but also for his leadership. He was the Dean of the Veterinary School from 1992 through 1998. Following this, he assumed the role of Vice-rector for Research from 1998 to 2002 and then progressed to the position of Rector of the University, a role he held from 2002 until 2009.

Ferrer's Contributions to Veterinary Science

Dr. Ferrer’s research interests encompass a wide range of dermatological conditions, with a significant focus on cutaneous infections like canine leishmaniosis. His work extends to understanding canine atopic dermatitis and the genetic underpinnings of skin diseases. These contributions have not only advanced veterinary dermatology but also offered practical solutions for everyday clinical challenges​​​​.

Dr. Ferrer’s upcoming lecture at LeishVet ALIVE 2, titled “The conundrum of clinical relapses in canine leishmaniosis,” promises to be a highlight of the event. This lecture is poised to shed light on the complexities and challenges in managing this prevalent disease, offering invaluable insights for both practitioners and researchers​​.

Why Attend Dr. Ferrer's Lecture?

Attending Dr. Ferrer’s lecture is an opportunity to glean knowledge from his vast experience and groundbreaking research. His perspective on canine leishmaniosis is expected to be both enlightening and transformative, offering new approaches and understandings that can be applied in clinical and research settings.

Conclusion: Don't Miss Out on LeishVet ALIVE 2!

LeishVet ALIVE 2, 2024 is more than a conference; it’s a gateway to the forefront of veterinary medicine, particularly in the realm of Leishmaniasis. Dr. Ferrer’s lecture is a must-attend for anyone seeking to deepen their understanding and enhance their practice in this field.

Don’t let this opportunity pass you by. Register now for LeishVet ALIVE 2 and join us, either in person in Nice or online, to experience the wealth of knowledge and innovation that Dr. Lluis Ferrer and other experts bring to the table. Register Here

Speaker Profile: Dr Jorge Alvar

Speaker Profile: Dr Jorge Alvar

Dr. Jorge Alvar will be a Keynote speaker at ALIVE 2024 giving the opening ceremony lecture: Control of visceral leishmaniasis: successes, risks and expectations

A Pioneer in the Fight Against Leishmaniasis

Welcome to the life and work of Dr. Jorge Alvar, a renowned figure in the world of medical research, specifically in the battle against Leishmaniasis. Dr. Alvar’s upcoming keynote lecture at ALIVE 2024, set in the picturesque city of Nice from April 18-20, 2024, is not just an event – it’s an insightful rendezvous with one of the most distinguished minds in tropical medicine.

His extensive career, from his early days at the Institute of Health Carlos III to his impactful role at the Drugs for Neglected Disease initiative (DNDi) in Geneva, has been marked by relentless dedication to combating neglected tropical diseases. With over 40 years of experience, his extensive list of publications has garnered more than 26,000 citations, and he boasts an h-index of 69. Additionally, he holds membership in the prestigious Royal Academy of Medicine of Spain.

Dr. Alvar's Journey: From Local Scientist to Global Health Crusader

In the realm of tropical medicine, few names resonate as profoundly as that of Dr. Jorge Alvar. His journey, originating from the prestigious halls of the University of Madrid, where he earned his medical degree and PhD, has been nothing short of extraordinary. Dr. Alvar’s passion for combating parasitic diseases led him to further his expertise with a master’s degree in Malaria & Environmental Health from Carabobo University, Venezuela, and a diploma in Tropical Medicine & Parasitology from Hamburg, Germany.

His early career saw him immersed in the world of parasitology and public health, working diligently at the Institute of Health Carlos III. Here, Dr. Alvar not only honed his skills as a scientist but also emerged as a leader, eventually heading the Department of Parasitology. His tenure was marked by significant strides in confronting parasitic epidemics and establishing a public health laboratory in Equatorial Guinea, a testament to his dedication to improving global health.

The turn of the millennium brought new challenges and opportunities for Dr. Alvar. In 2000, he assumed the role of Director of the National Centre of Tropical Medicine. But perhaps his most notable contribution to global health came with his role in the Leishmaniasis World Program at the World Health Organization (WHO). There, he spearheaded strategic plans and control programs in East Africa and South Asia, tackling the disease head-on.

Dr. Alvar’s expertise and impact extended beyond organizational boundaries when he joined the DNDi in Geneva. As the head, and later Senior Adviser, of the drug development program for Leishmaniasis, he played a pivotal role in advancing research and treatment for this neglected disease. His efforts have not gone unnoticed; his research in epidemiology and diagnosis of Leishmaniasis has earned him numerous awards and recognition, including an impressive citation record and a high h-index factor.

Throughout his career, Dr. Alvar has been a symbol of optimism and innovation in the fight against Leishmaniasis. His work has spanned continents, involving him in over 30 research projects or clinical trials and bringing his expertise to communities in dire need. As a member of the Royal Academy of Medicine of Spain, his contributions to medical science and public health continue to inspire and drive progress in the field.

As we look forward to his keynote lecture at ALIVE 2024, it’s clear that Dr. Alvar’s journey is far more than a career; it’s a lifelong mission to eradicate one of the world’s most debilitating diseases. His story is not just one of scientific achievement but of profound human impact, a narrative that continues to unfold and inspire those dedicated to the field of tropical medicine and global health​​.

Tackling Neglected Tropical Diseases: The DNDi Approach

In the landscape of global health, the Drugs for Neglected Disease initiative (DNDi) stands as a towering testament to innovative and humanitarian approaches to medicine. Dr. Jorge Alvar’s involvement with DNDi marks a crucial chapter in his illustrious career, reflecting a profound commitment to addressing diseases often overlooked by mainstream medical research.

DNDi emerged from a noble vision: to bring much-needed attention and resources to the fight against neglected tropical diseases (NTDs). It was founded in 2003, following a decision by Médecins Sans Frontières to allocate part of their Nobel Peace Prize funds to this cause. This initiative signified a paradigm shift in how the medical community approached NTDs, including Leishmaniasis, which affects over a billion people, predominantly in impoverished communities.

Under Dr. Alvar’s guidance, DNDi focused on developing treatments that are not only effective but also accessible and easy to administer. This approach is crucial in areas where medical resources are scarce and the burden of disease is high. The initiative’s work, recognized through prestigious awards like the Princesa de Asturias Award for International Cooperation, underscores the impact of collaborative, non-profit research in changing the global health landscape.

Dr. Alvar’s role in DNDi was instrumental in steering the organization towards groundbreaking research and development. His leadership helped bridge the gap between scientific innovation and practical, life-saving applications in the field. The initiative’s success is a testament to Dr. Alvar’s vision of a world where the scourge of NTDs is a thing of the past, a vision that he continues to pursue with relentless passion and dedication.

A Decade of Progress and Challenge

Over the past decade, under the stewardship of Dr. Jorge Alvar and organizations like DNDi, there has been significant progress in combating Neglected Tropical Diseases (NTDs). This journey, however, is marked by both remarkable achievements and ongoing challenges.

The concerted international effort against NTDs has resulted in substantial strides forward. For instance, the past ten years have seen 500 million people no longer requiring NTD control programs. Diseases like lymphatic filariasis and trachoma have been eliminated as public health problems in several countries. The success stories extend to leishmaniasis in Southeast Asia and the near-eradication of Guinea worm disease.

However, these triumphs exist alongside persistent challenges. NTDs, closely linked to poverty, continue to demand substantial investment in research and healthcare infrastructure strengthening. Dr. Alvar stresses the critical need for continued focus on these diseases, underscoring their intimate connection to impoverished conditions and remote regions. The fight against NTDs is not just a medical challenge but also a socio-economic one, requiring holistic approaches and sustained efforts.

Moreover, the emergence of new challenges such as COVID-19 has disrupted control programs and funding, highlighting the fragility of progress and the need for resilience in public health initiatives. Dr. Alvar’s insights into these complex dynamics will be pivotal in his upcoming lecture at ALIVE 2024, offering a comprehensive view of the past achievements and future directions in the battle against NTDs​​​​.

The Broader Impact of Climate Change and Global Dynamics

In the intricate tapestry of global health, the impact of broader factors like climate change and population dynamics becomes increasingly evident, a theme that Dr. Jorge Alvar has often highlighted in his work. The phenomenon known as the “Great Acceleration,” driven by population growth and its associated activities, disproportionately affects developing countries. These countries, already burdened with neglected tropical diseases (NTDs), now face additional challenges posed by climate change.

The rise in global temperatures, now seemingly unstoppable, has immediate health implications. It not only exacerbates malnutrition and increases the incidence of violent episodes but also influences the spread of NTDs. Diseases once confined to tropical and subtropical zones are now encroaching upon new areas, including temperate regions. A stark example is the Aedes albopictus mosquito, the carrier of diseases like chikungunya and dengue, which has expanded its habitat to southern Europe.

Furthermore, environmental degradation is forcing wildlife, potential reservoirs of various pathogens, closer to human habitats. This proximity increases the risk of new zoonoses, diseases transmitted from animals to humans, a significant concern in tropical regions where 60% of emerging diseases are zoonotic in origin.

Dr. Alvar’s insights into these global dynamics underline the interconnected nature of NTDs, environmental change, and public health. His perspective sheds light on the necessity of a multidimensional approach to health, one that integrates environmental and social factors into the fight against diseases like Leishmaniasis​​.

Innovations in Treatment and Healthcare

In the realm of medical research and treatment, innovation is the key to progress. This is particularly true in the work of Dr. Jorge Alvar, whose contributions to Leishmaniasis treatment have been groundbreaking. His approach has not only improved existing treatments but has also introduced new, more effective methods.

Under Dr. Alvar’s guidance, the treatment of Leishmaniasis, especially in patients co-infected with HIV, has seen remarkable improvements. Traditional treatment methods, once only moderately effective, have evolved into more efficient regimes, dramatically increasing the success rate. These advancements are a testament to Dr. Alvar’s deep understanding of the disease and his commitment to finding more effective solutions.

One of the hallmarks of his approach is the development of treatments that are easier to administer. The move from injectables to oral medications, for example, represents a significant step forward in patient care. This shift not only reduces the risks associated with injections but also makes treatment more accessible, especially in remote areas where medical resources are scarce.

Dr. Alvar’s innovative strategies in tackling Leishmaniasis are expected to be a major highlight of his keynote speech at ALIVE 2024. His work exemplifies the importance of continuous research and adaptation in the field of tropical medicine and offers hope for better treatment methods for those affected by this disease​​.

Conclusion: The Road Ahead

As we conclude this exploration of Dr. Jorge Alvar’s significant contributions to the field of tropical medicine, particularly in combating Leishmaniasis, it becomes evident that his journey is a beacon of hope and a source of inspiration. His accomplishments, from groundbreaking research to innovative treatment methods, have not only advanced medical science but also transformed the lives of countless individuals affected by neglected tropical diseases.

Looking forward to his keynote lecture at ALIVE 2024, it’s clear that Dr. Alvar’s insights will be invaluable to both veterinarians and researchers. His unique perspective, blending scientific expertise with a deep understanding of the social and environmental factors affecting health, makes his address a must-attend event for professionals in the field.

Join ALIVE 2024

As we draw inspiration from Dr. Jorge Alvar’s journey and achievements, we invite you to join us at ALIVE 2024. This conference presents a unique opportunity to engage with leading minds in the field of Leishmaniosis research and treatment. Whether you are a veterinarian eager to learn about the latest developments in combating this disease, or a researcher seeking insights into innovative treatment methodologies, ALIVE 2024 is the place to be.

Register now to be part of this enlightening experience in Nice. Engage with experts, share knowledge, and contribute to the global effort in tackling Leishmaniosis and other neglected tropical diseases. Let’s come together to make a difference in the world of tropical medicine.


  1. The Lancet Global Health Article:"New Tools and Strategies for Tuberculosis Diagnosis, Care, and Elimination," The Lancet Global Health, 2021. Available at: The Lancet.
  2. Real Instituto Elcano Blog Post:"Un premio a la investigación terapéutica en favor de los más pobres," Real Instituto Elcano, 2023. Available at: Real Instituto Elcano.
  3. La Voz de Asturias Article:"Jorge Álvar: 'El modelo funciona, hemos desarrollado 12 medicamentos y tendremos 15 en 2030'," La Voz de Asturias, October 2023. Available at: La Voz de Asturias.
  4. Google Scholar Profile: Google Scholar profile of an individual researcher. Available at: Google Scholar.
  5. El País Article:"La Iniciativa para Enfermedades Desatendidas, premio Princesa de Asturias de Cooperación Internacional 2023," El País, June 2023. Available at: El País.

Dive Deep into Animal Leishmaniosis: ALIVE 2024 Congress in Nice Offers Research, Clinical Insights, and Expert Discussions

Dive Deep into Animal Leishmaniosis: ALIVE 2024 Congress in Nice Offers Research, Clinical Insights, and Expert Discussions

Exciting news for all veterinary professionals and researchers! The Second International Congress on Animal Leishmaniosis (ALIVE 2) is scheduled to be held from the 18th to the 20th of April, 2024, in the picturesque city of Nice, France.

What to Expect at ALIVE 2024?

The LeishVet Scientific Committee is gearing up to host this event in a hybrid format, ensuring that participants can engage both in-person and view virtually. This congress promises to bring together the crème de la crème of experts specializing in animal leishmaniosis. It’s not just a gathering of experts, but also an opportunity to meet all the LeishVet members.

The second ALIVE congress, also known as the Animal Leishmaniosis International Veterinary Event, has an enriching Scientific Program lined up. Just like its inaugural edition, the program will be bifurcated into two main streams:

  • Research Stream: Dive deep into the latest findings and advancements in the field of animal leishmaniosis
  • Clinical Stream: Gain insights into the clinical diagnosis and treatment methodologies for this significant zoonotic disease

In addition to these streams, attendees will have the exclusive chance to participate in round table discussions alongside esteemed speakers and LeishVet members. These discussions will revolve around real clinical cases, epidemiology, diagnosis, treatment, and preventive measures related to animal leishmaniosis.

ALIVE 2024 Congress: Scientific Programme Overview

  • Kick-off Evening: Attendees are welcomed with a cocktail at the Radisson Blu’s Rooftop, setting the ambiance for the upcoming sessions.
  • Both days commence with an Informal Get Together for young scientists and clinicians, fostering collaboration and networking.
  • Notable sessions include discussions on:
    • ophthalmic challenges in animal leishmaniosis
    • Leishmania donovani in India
    • other Leishmania species infecting dogs
    • the impact of Phlebotomine sand flies on health.
    • when clinicians should suspect feline leishmaniosis
    • clinical relapses in canine leishmaniosis
    • unexpected lessons of leishmaniosis
    • the role of extracellular vesicles in canine leishmaniosis
  • Keynote speakers like Carla MaiaChristopher Fernandez-Prada, Christine Petersen, Filipe Dantas-Torres, Marta Leiva, Alessandra Fondati, Manolis Saridomichelakis and Lluís Ferrer share their expertise on various facets of leishmaniosis.
  • Interspersed with these sessions are Oral Communications, Round Tables, and Poster Sessions, offering a platform for diverse voices in the field.

The highlight of Friday evening is a Gala Dinner, while the congress concludes on Saturday with a formal Closing Ceremony.

Venue Details

The congress is set to be hosted at the luxurious Hotel Radisson Blu, located on the iconic Promenade des Anglais in Nice. The hotel is conveniently situated just 4 km away from the Nice Côte d’Azur International Airport and a mere 5 km from the city’s bustling center. While most of the congress activities will be held within the hotel premises, attendees can look forward to a special Gala Dinner with complimentary transportation which will be arranged for this dinner event.

For those who might not be able to attend in person, don’t fret! The entire event will be streamed online, ensuring that no one misses out on this unique learning opportunity.

Stay Updated

For more detailed information about the ALIVE congress, including registration details and the full program, visit the official website at You can also follow updates on their social media channels. Should you have any questions or require further information, feel free to reach out to the organizers at

Don't miss out on this golden opportunity to learn, network, and collaborate with the best in the field of animal leishmaniosis. Mark your calendars and see you in Nice!

Registration is open! Enjoy Early Bird Rates at LeishVet ALIVE 2024

The Animal Leishmaniosis International Veterinary Event 2024 is now open for registration.

Speakers from Brazil, Canada, Greece, Italy, Portugal, Spain and the USA will deliver the presential and online event on 18th-20th April, for delegates from across the world to find out about the state of research and clinical practice in animal Leishmaniosis.

Join LeishVet and your veterinary community either online or in Nice for three days of inspiration, conversation, and education taught by the best and brightest in the world of animal Leishmaniosis. Registration is now open for the ALIVE 2024 event. The conference will take place next spring in Nice, France, from 18th-20th April, 2024, and we can’t wait to see you there!

Expand your skillset, gain practical knowledge, and learn the latest information on hot topics impacting Leishmaniosis today. Whatever your career stage or focus area, ALIVE 2024 has what you need to grow and advance in your career.

We will explore these tracks:

  • Epidemiology.
  • Basic to clinical immunology.
  • Genomics, transcriptomics, proteomics and metabolomics of leishmaniosis, susceptibility and resistance to infection and disease.
  • Pathogenesis.
  • Clinical and diagnostic aspects.
  • Treatment, prognosis and monitoring.
  • Preventative tools.

All 24 hours of educational sessions will be available on-demand to convention attendees after the conference.

Further details can be found on the ALIVE 2, 2024 (Animal Leishmaniosis International Veterinary Event 2024).

We look forward to seeing you at ALIVE 2 either Online or in Nice!

Submit your abstract to ALIVE

Abstract Final Extension

Submit your Abstract

The ALIVE 2 CONGRESS 2024 invites veterinarians and researchers to submit abstracts with clinical or research content related to animal leishmaniosis.

Read GuidelinesSubmission Form

Key Dates

  • 1st July 2023 | Abstract Submission Opens
  • 2nd October 2023, Midnight CET Final Extension: 30th November 2023, Midnight CET | Abstract Submission Deadline
  • From 18th December 2023 | Abstract Notification

Once an abstract has been accepted, the presenting author must register for the ALIVE Congress before the 10th January 2024. Anyone whose abstract has been accepted and has not registered by the above-mentioned date will lose the option to present their work in any format whatsoever.

Submit your abstract to ALIVE

Submit your Abstract from July 1st, 2023

Submit your Abstract

The ALIVE 2 CONGRESS 2024 invites veterinarians and researchers to submit abstracts with clinical or research content related to animal leishmaniosis.

Read GuidelinesSubmission Form

Key Dates

  • 1st July 2023 | Abstract Submission Opens
  • 2nd October 2023, Midnight CET | Abstract Submission Deadline
  • From 18th December 2023 | Abstract Notification

Once an abstract has been accepted, the presenting author must register for the ALIVE Congress before the 10th January 2024. Anyone whose abstract has been accepted and has not registered by the above-mentioned date will lose the option to present their work in any format whatsoever.

ALIVE 2, Save the Date - Nice 18 to 20 April 2024

ALIVE 2, 2024 to be held in Nice

Alive 2, 2024 @ Nice, France

ALIVE's second edition will take place in Nice, France

The Organizational Committee for ALIVE has chosen Nice for this second edition. ALIVE 2 (Animal Leishmaniosis International Veterinary Event) will be held from the 18th to the 20th of April, 2024.

The iconic city of Nice has been chosen for its kind weather, its famous savoir faire, its beautiful location on the Côte d’Azur and the great connections and services that it offers for, once again, what will be an outstanding event.

The pleasant temperatures of Nice at this time of the year, from 14º to 18ºC and the many hours of sun will certainly allow all our international attendees to enjoy a walk down the Promenade des Anglais and even a swim in the sea.

The Côte d’Azur International Airport, serves over 12 million passengers annually and it offers 114 direct flight destinations, operated by 57 companies, regularly travelling to and from 43 countries.

The Organizational Committee can count on a group of event professionals that will help ALIVE 2 become a successful and inspiring scientific event.

We look forward to seeing you in Nice!

Press Release ALIVE Congress 2022

We are pleased to communicate that the ALIVE Congress (Animal Leishmaniosis International Veterinary Event), organized by the LeishVet group, was successfully held in Málaga between March 31st and April 2nd, 2022. Its international character has allowed a total of 197 (in person) and 202 (online) researchers, practitioners and dermatologists from 26 countries to come together for the event.

This congress featured Speakers, in this field, of recognized international standing, in addition to a large number of researchers presenting their research results through oral communications or posters.

For LeishVet and the entire Organizing Committee, it has been an excellent opportunity to meet again, to share knowledge and to be inspired by the enthusiasm, cooperation, continuous learning of the participants and, in short, to keep up to date with the advances in research and clinical management of a disease that interests us all as “leishmaniacs”.

We would like to give special thanks to all the Sponsors (ELANCO, IDEXX, LETI PHARMA, MSD, BOEHRINGER INGELHEIM, VIRBAC, ECUPHAR, CEVA, BIOCLIN VET, Consejo Andaluz de Colegios Oficiales de Veterinarios and the Colegio Oficial de Veterinarios de Málaga) and to the members of the Scientific Committee for their active participation and to all the participants for their contributions.

Guadalupe Miró
President of LeishVet and the Organizing Committee